Drug Database
Back to search

Switzerland· 35501029

Tavegyl, Injektionslösung

A clemastine product containing clemastinum, registered in Switzerland by Gebro Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC R06AA04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTavegyl, InjektionslösungATCR06AA04REGISTER NO.35501029PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about clemastinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Clemastine is registered in 11 of 19 countries.

Countries holding a registration under ATC R06AA04 (clemastine), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 6 of them publish a price we can compare per daily dose
Search clemastine products by name

Clemastine · ATC R06AA04

11 / 19 countries

  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
clemastinum
Manufacturer
Gebro Pharma AG
Country
Switzerland (CH)
ATC code
R06AA04
ATC class
Clemastine
Defined daily dose
2 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680355010294
    5 Amp 2 ml
    CHF 17.3

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

321 interactions on record for clemastine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check clemastine against other medicinesHow interaction checks work

Clemastine · interactions on record

321 records

  • 9 severe
  • 309 moderate
  • 3 minor

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • Sodium oxybateN01AX11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Clemastine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All clemastine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Germany · Tavegil, Tavegil Tabletten
  • Denmark · Clemastine Macure
  • Estonia · Tavegyl
  • Finland · Clemastine Macure
  • United Kingdom (Northern Ireland) · Tavegil
  • Iceland · Tavegyl
  • Lithuania · Clemastinum Pph, Tavegyl
  • Latvia · Tavegyl
  • Netherlands · Clemastine Macure, Clemastine Milstein
  • Norway · Clemastine Macure
  • Poland · Clemastinum Aflofarm, Clemastinum Hasco
  • Portugal · Tavégyl, Tavist
  • Sweden · Clemastine Macure, Tavegyl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dafa0fe9-30ab-4c67-ac8f-aa4eb71f370b
GET /v1/drugs/dafa0fe9-30ab-4c67-ac8f-aa4eb71f370b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "clemastinum 2 mg",
  "valid_from": "1968-03-15",
  "limitations": null,
  "galenic_form": "Inj Lös 2 mg/2ml i.m./i.v.",
  "therapeutic_area": null,
  "sl_inclusion_date": "1968-03-15",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about clemastine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console